Discover 2,450 paid clinical trials in North Carolina. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
From paid studies for healthy volunteers to condition-specific trials, North Carolina offers a wide range of clinical research opportunities. Leading medical centers in Charlotte, Raleigh, and Durham are seeking participants, providing access to innovative treatments and comprehensive care.
Filter
1
Filter results
Results: 2,450
Active & Responsive
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
for
Electronic Cigarette Related Lung Damage
Location: Charlottesville VA, Durham NC
Sponsor: Y. Michael Shim, MD
Sex: All
Age: 18 - 35
Code: NCT06856525
Phase2, Phase3, Recruiting
Active & Responsive
Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
for
Coronary Artery Disease Risk Factors Multiple,
Location: New York NY, Durham NC, Hiram GA, Birmingham AL,
Sponsor: Duke University
Sex: All
Age: 30 - 60
Code: NCT07232069
Phase3, Recruiting
Active & Responsive
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
for
Stomatitis
Location: Wynnewood PA, East Syracuse NY, Wilson NC, Athens GA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07357597
Recruiting
Active & Responsive
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
for
Sjögren´s Disease
Location: Rimouski, Charlotte NC, Tampa FL, Clearwater FL,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07621809
Phase3, Recruiting
Active & Responsive
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, New York NY, Montreal, Winston-Salem NC,